You are leaving this site!
By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?
The Jeffrey Modell Foundation is a nonprofit research foundation devoted to PI that sponsors symposia and workshops; supports research and training; and provides diagnostic, clinical, and educational services. For more information or referrals to immunologists at major medical centers across the United States, call the 24-hour-a-day national hotline at 1-800-JEFF-844 or visit www.jmfworld.com.
The Immune Deficiency Foundation (IDF) is a nonprofit foundation with chapters throughout the United States that serve patients, families, and medical professionals dealing with PI. The IDF supports scientific research and training, fosters public education, and offers a Patient Support Line at 1-800-296-4433. For more information, visit www.primaryimmune.org.
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an association of national patient organizations dedicated to improving awareness, access to early diagnosis, and optimal treatments for patients with PI throughout the world. Established in 1992, IPOPI works as the global advocate for the PI patient community in cooperation with its National Member Organizations (NMOs) and key PI stakeholders. For more information, visit www.ipopi.org.
This information is being provided for your reference only. ADMA Biologics is not affiliated with and does not endorse any of the organizations listed above.
BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
BIVIGAM is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and history of hypersensitivity.
Thrombosis may occur following treatment with IGIV products, including BIVIGAM. Thrombosis may occur in the absence of known risk factors.
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/ markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer BIVIGAM at the minimum dose and infusion rate practicable.
In patients at risk of developing acute renal failure, renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output need to be monitored.
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV therapy. Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments; AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.
As hemolysis can develop subsequent to treatment with IGIV products, monitor patients for hemolysis and hemolytic anemia. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). If TRALI is suspected, test the product and patient for antineutrophil antibodies.
Because BIVIGAM is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Passive transfer of antibodies with IGIV treatment may yield positive serological testing results, with the potential for misleading interpretation.
Serious adverse reactions observed in clinical trial subjects receiving BIVIGAM were vomiting and dehydration in one subject. The most common adverse reactions to BIVIGAM (reported in ≥ 5% of clinical study subjects) were headache, fatigue, infusion site reaction, nausea, sinusitis, blood pressure increase, diarrhea, dizziness, and lethargy.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
For more information about BIVIGAM, please see full Prescribing Information.